Ardeagen is leveraging over 30 years of biologics drug development experience of its founder, Morris Z. Rosenberg.  Dr. Rosenberg has held positions at Biogen, Eli Lilly, Seattle Genetics, and at Immunomedics. During his tenure at Seattle Genetics, Dr. Rosenberg helped develop one of the world’s leading antibody drug conjugate platforms and played a key role in the launch of Adcetris for Hodgkin Lymphoma and ALCL.  At Immunomedics, he played a played a pivotal role in the approval and launch of Trodelvy for Triple Negative Breast cancer.